IL-17/IL-17A Antibody (881309) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # FAB7211JF635
Conjugate
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
CyTOF-ready, Flow Cytometry
Label
Janelia Fluor 635
Antibody Source
Monoclonal Rat IgG2B Clone # 881309
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant mouse IL‑17/IL‑17A
Thr22-Ala158
Accession # Q62386
Thr22-Ala158
Accession # Q62386
Specificity
Detects mouse IL‑17/IL‑17A in direct ELISAs.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2B
Applications for IL-17/IL-17A Antibody (881309) [Janelia Fluor® 635]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
0
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-17/IL-17A
Long Name
Interleukin 17
Alternate Names
CTLA-8, CTLA8, IL-17A, IL17, IL17A
Gene Symbol
IL17A
Additional IL-17/IL-17A Products
Product Documents for IL-17/IL-17A Antibody (881309) [Janelia Fluor® 635]
Product Specific Notices for IL-17/IL-17A Antibody (881309) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...